Ddx21 mutant peptide is an effective neoantigen in prophylactic lung cancer vaccines and activates long-term anti-tumor immunity
These results suggest that the Ddx21MT is a highly effective neoantigen that can activate anti-tumor immunity, which can serve as an important component in developing a lung cancer vaccine and is expected to be used in combination with other immunotherapy approaches.
Authors
- Yimeng Xia (ORCID: https://orcid.org/0000-0001-5187-657X)
- Yijia He
- Baisui Feng (ORCID: https://orcid.org/0000-0002-1024-3191)
- Junzhi Yu (ORCID: https://orcid.org/0000-0002-6347-572X)
- Yaohe Wang (ORCID: https://orcid.org/0000-0003-2367-6313)
- Ruixian Liu (ORCID: https://orcid.org/0000-0002-3065-6743)
- Zhe Zhang (ORCID: https://orcid.org/0000-0003-2365-2362)
- Zhihong Wang (ORCID: https://orcid.org/0000-0001-7341-0201)
- Na Wang (ORCID: https://orcid.org/0000-0001-9179-4130)
- Yaxing Sun
- Dan Pu (ORCID: https://orcid.org/0000-0001-6628-9714)
- Yan Liu (ORCID: https://orcid.org/0000-0002-2471-2112)
- Yanru Zhang
- Shiyang Ning
Institutions
- Queen Mary University of London (GB)
- Zhengzhou University (CN)
- Second Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1500417
- Citations
- 1
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.80